Loading...

HBIO HARVARD BIOSCIENCE INC Management Changes 8-K Filing

HRVR

HB

HARVARD BIOSCIENCE INC

(HBIO)

2025 8-K

Corporate Update

Financial Results Announced

Management Changes

Stock Split Approved

Financial Results Update

Operational Changes

By-law Amendment

Investor Update

Loan Agreement Details

Credit Agreement Update

Financial Results Announced

Nasdaq Compliance Update

Board Appointment

Management Change

Notice of Delisting

Financial Statements

Director Departure

Delisting Notice

Financial Results

Credit Agreement Amendment

Financial Results

Annual Meeting of Stockholders

Credit Agreement Amendment

Compensation Committee Appr...

Financial Results Announcement

Financial Condition and Res...

Appointment of CFO

Annual Meeting of Stockholders

Compensation Committee Appr...

Financial Results Announcement

Resignation of CFO

External Links:

Harvard Bioscience, Inc. received a notice on April 4, 2025, from Nasdaq stating it does not meet the minimum bid price requirement for continued listing, and the Chief Financial Officer, Jennifer Cote, resigned on April 7, 2025, with Mark Frost appointed as Interim CFO on April 10, 2025.

AI Assistant

HARVARD BIOSCIENCE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.